Patient baseline characteristics
| Characteristic . | Value, N = 52 . |
|---|---|
| Age (years) – median (range) | 66 (43–78) |
| ≥ 65 – n (%) | 28 (54%) |
| Male sex – n (%) | 23 (44%) |
| Extramedullary disease – n (%) | 32 (62%) |
| High baseline marrow burden (≥ 50%) – n (%) | 18 (35%) |
| Circulating plasma cells at pre-LD – n (%) | 8 (15%) |
| ECOG performance status at pre-LD – n (%) | |
| 0 | 14 (27%) |
| 1 | 28 (54%) |
| 2 | 8 (15%) |
| 3 | 2 (4%) |
| R-ISS stage at CAR T-cell infusion – n (%) | |
| I | 9 (18%) |
| II | 32 (65%) |
| III | 8 (16%) |
| Unknown | 3 |
| High-risk cytogenetics – n (%) | 19 (40%) |
| del(17p) | 13 (28%) |
| t(4;14) | 7 (15%) |
| t(14;16) | 1 (2%) |
| Unknown | 5 |
| Prior lines of therapy – median (range) | 6 (4–13) |
| > 4 – n (%) | 44 (85%) |
| Prior autologous stem cell transplant – n (%) | 42 (81%) |
| Prior allogeneic stem cell transplant – n (%) | 0 (0%) |
| Prior BCMA-directed therapy – n (%) | 5 (10%) |
| Bridging therapy – n (%) | 41 (79%) |
| Alkylating bridging therapy – n (%) | 22 (42%) |
| Days from last treatment to LD – median (range) | 21 (3–48) |
| Refractory status – n (%) | |
| Immunomodulatory agent | 50 (96%) |
| Proteasome inhibitor | 49 (94%) |
| Daratumumab | 49 (94%) |
| Double-refractory disease | 48 (92%) |
| Triple-refractory disease | 45 (87%) |
| Penta-refractory disease | 23 (44%) |
| Eligible for KarMMa trial at apheresis – n (%) | 13 (25%) |
| Characteristic . | Value, N = 52 . |
|---|---|
| Age (years) – median (range) | 66 (43–78) |
| ≥ 65 – n (%) | 28 (54%) |
| Male sex – n (%) | 23 (44%) |
| Extramedullary disease – n (%) | 32 (62%) |
| High baseline marrow burden (≥ 50%) – n (%) | 18 (35%) |
| Circulating plasma cells at pre-LD – n (%) | 8 (15%) |
| ECOG performance status at pre-LD – n (%) | |
| 0 | 14 (27%) |
| 1 | 28 (54%) |
| 2 | 8 (15%) |
| 3 | 2 (4%) |
| R-ISS stage at CAR T-cell infusion – n (%) | |
| I | 9 (18%) |
| II | 32 (65%) |
| III | 8 (16%) |
| Unknown | 3 |
| High-risk cytogenetics – n (%) | 19 (40%) |
| del(17p) | 13 (28%) |
| t(4;14) | 7 (15%) |
| t(14;16) | 1 (2%) |
| Unknown | 5 |
| Prior lines of therapy – median (range) | 6 (4–13) |
| > 4 – n (%) | 44 (85%) |
| Prior autologous stem cell transplant – n (%) | 42 (81%) |
| Prior allogeneic stem cell transplant – n (%) | 0 (0%) |
| Prior BCMA-directed therapy – n (%) | 5 (10%) |
| Bridging therapy – n (%) | 41 (79%) |
| Alkylating bridging therapy – n (%) | 22 (42%) |
| Days from last treatment to LD – median (range) | 21 (3–48) |
| Refractory status – n (%) | |
| Immunomodulatory agent | 50 (96%) |
| Proteasome inhibitor | 49 (94%) |
| Daratumumab | 49 (94%) |
| Double-refractory disease | 48 (92%) |
| Triple-refractory disease | 45 (87%) |
| Penta-refractory disease | 23 (44%) |
| Eligible for KarMMa trial at apheresis – n (%) | 13 (25%) |
Patient baseline characteristics prior to idecabtagene vicleucel (ide-cel) infusion: LD, lymphodepletion chemotherapy; ECOG, Eastern Cooperative Oncology Group; R-ISS: Revised International Staging System; N = 49 due to 3 patients with R-ISS unknown; BCMA, B-cell maturation antigen. High-risk cytogenetics includes del(17p), t(4;14), and t(14;16) as per the KarMMa trial, N = 47 due to 5 patients with mutation status unknown; double-refractory disease indicates refractory to an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI); triple-refractory disease indicates refractory to an IMiD, PI, and daratumumab; penta-refractory disease indicates refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab.